Converge Bio Funding Round

6/1/2026

Debt

$2,500,000

Undisclosed

The company intends to use the funds to expand its drug modeling platform into crop genomics, build multimodal long-context DNA foundation models, and accelerate breeding timelines for climate-resilient plants.

Private & Independent

Biopharmaceutical

108 W. 13th Street 100
Wilmington, DE 19801
USA

Undisclosed

Converge Bio is on a mission to empower biotech and pharmaceutical companies with Generative AI solutions to discover more effective drugs faster. We train Generative AI models on the core biological languages of DNA, RNA and protein sequences and build around our models experimentally validated solutions any scientist can use. Our ultimate goal is that at any given stage of the drug discovery life cycle, scientists will have a dedicated AI solution to support them. To date, we have rolled out to our customer base systems supporting target discovery, antibody design, protein manufacturing optimization, and biomarker discovery.